List of Opzelura drug patents

Opzelura is owned by Incyte Corp.

Opzelura contains Ruxolitinib Phosphate.

Opzelura has a total of 22 drug patents out of which 0 drug patents have expired.

Opzelura was authorised for market use on 21 September, 2021.

Opzelura is available in cream;topical dosage forms.

Opzelura can be used as for topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

The generics of Opzelura are possible to be released after 20 November, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(4 years from now)

US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(4 years from now)

US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US10639310 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US9974790 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Dec, 2026

(3 years from now)

US10639310

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2027

(4 years from now)

US9974790

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Jun, 2027

(4 years from now)

US9079912

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Jun, 2027

(4 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US10610530 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(5 years from now)

US8415362

(Pediatric)

INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2028

(5 years from now)

US7598257

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Jun, 2028

(5 years from now)

US8722693

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8822481

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US10610530

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US11219624 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US10869870 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US10758543 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US10869870

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US11219624

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US10758543

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 21, 2024
New Indication (I) Jul 18, 2025
Pediatric Exclusivity (PED) Mar 21, 2025

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Dosage: CREAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in